Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
Braz. dent. j ; 21(6): 491-498, 2010. ilus, tab
Article Dans Anglais | LILACS | ID: lil-572294

Résumé

The aim of this study was to investigate the effects of low-level laser therapy (LLLT) by using gallium aluminum arsenide (GaAlAs) diode laser on human osteoblastic cells grown on titanium (Ti). Osteoblastic cells were obtained by enzymatic digestion of human alveolar bone and cultured on Ti discs for up to 17 days. Cells were exposed to LLLT at 3 J/cm2 (wavelength of 780 nm) at days 3 and 7 and non-irradiated cultures were used as control. LLLT treatment did not influence culture growth, ALP activity, and mineralized matrix formation. Analysis of cultures by epifluorescence microscopy revealed an area without cells in LLLT treated cultures, which was repopulated latter with proliferative and less differentiated cells. Gene expression of ALP, OC, BSP, and BMP-7 was higher in LLLT treated cultures, while Runx2, OPN, and OPG were lower. These results indicate that LLLT modulates cell responses in a complex way stimulating osteoblastic differentiation, which suggests possible benefits on implant osseointegration despite a transient deleterious effect immediately after laser irradiation.


Este estudo teve como objetivo investigar o efeito do laser diodo de gálio-alumínio-arsênio (GaAlAs) em células osteoblásticas humanas cultivadas sobre discos de Ti. Para tanto, células osteoblásticas foram obtidas por digestão enzimática de osso alveolar humano e cultivadas sobre discos de Ti por 17 dias. As células foram submetidas à irradiação no 3º e 7º dias na dose de 3 J/cm2 e comprimento de onda de 780 nm e células não irradiadas foram usadas como controle. A irradiação não alterou a proliferação celular, atividade de ALP e formação de matriz mineralizada. Microscopia por epifluorescência indicou que após 24 h da aplicação do laser, as culturas irradiadas apresentaram áreas sem células, que mais tarde foram repovoadas por células em fase de proliferação e menos diferenciadas. O laser aumentou a expressão gênica relativa da ALP, OC, BSP e BMP-7 e reduziu a de RUNX2, OPN e OPG. Os resultados indicam que a terapia com laser modula de forma complexa as respostas celulares, estimulando a diferenciação osteoblástica. Assim, é possível sugerir possíveis benefícios do laser na osseointegração de implantes de Ti apesar do efeito deletério às células imediatamente após a irradiação.


Sujets)
Humains , Trame osseuse/croissance et développement , Expression des gènes/effets des radiations , Photothérapie de faible intensité , Ostéo-intégration/effets des radiations , Ostéoblastes/effets des radiations , Analyse de variance , Phosphatase alcaline/biosynthèse , Phosphatase alcaline/génétique , /biosynthèse , /génétique , Cellules cultivées/effets des radiations , Collagène de type I/biosynthèse , Collagène de type I/génétique , Sous-unité alpha 1 du facteur CBF/biosynthèse , Sous-unité alpha 1 du facteur CBF/génétique , Sialoprotéine liant les intégrines/biosynthèse , Sialoprotéine liant les intégrines/génétique , Molécule-1 d'adhérence intercellulaire/biosynthèse , Molécule-1 d'adhérence intercellulaire/génétique , Lasers à semiconducteur/usage thérapeutique , Ostéoblastes/métabolisme , Ostéocalcine/biosynthèse , Ostéocalcine/génétique , Ostéopontine/biosynthèse , Ostéopontine/génétique , Ostéoprotégérine/biosynthèse , Ostéoprotégérine/génétique , Ligand de RANK/biosynthèse , Ligand de RANK/génétique , Statistique non paramétrique , Titane
2.
Experimental & Molecular Medicine ; : 87-98, 2010.
Article Dans Anglais | WPRIM | ID: wpr-81946

Résumé

Parathyroid hormone-related protein (PTHrP) is synthesized by diverse tissues, and its processing produces several fragments, each with apparently distinct autocrine and paracrine bioactivities. In bone, PTHrP appears to modulate bone formation in part through promoting osteoblast differentiation. The putative effect of PTH-like and PTH-unrelated fragments of PTHrP on human mesenchymal stem cell (MSCs) is not well known. Human MSCs were treated with PTHrP (1-36) or PTHrP (107-139) or both (each at 10 nM) in osteogenic or adipogenic medium, from the start or after 6 days of exposure to the corresponding medium, and the expression of several osteoblastogenic and adipogenic markers was analyzed. PTHrP (1-36) inhibited adipogenesis in MSCs and favoured the expression of osteogenic early markers. The opposite was observed with treatment of MSCs with PTHrP (107-139). Moreover, inhibition of the adipogenic differentiation by PTHrP (1-36) prevailed in the presence of PTHrP (107-139). The PTH/PTHrP type 1 receptor (PTH1R) gene expression was maximum in the earlier and later stages of osteogenesis and adipogenesis, respectively. While PTHrP (107-139) did not modify the PTH1R overexpression during adipogenesis, PTHrP (1-36) did inhibit it; an effect which was partially affected by PTHrP (7-34), a PTH1R antagonist, at 1 microM. These findings demonstrate that both PTHrP domains can exert varying effects on human MSCs differentiation. PTHrP (107-139) showed a tendency to favor adipogenesis, while PTHrP (1-36) induced a mild osteogenic effect in these cells, and inhibited their adipocytic commitment. This further supports the potential anabolic action of the latter peptide in humans.


Sujets)
Humains , Adipogenèse/effets des médicaments et des substances chimiques , Phosphatase alcaline/biosynthèse , Antigènes de différenciation/biosynthèse , Moelle osseuse/anatomopathologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Cellules cultivées , Sous-unité alpha 1 du facteur CBF/biosynthèse , Milieux de culture , Régulation de l'expression des gènes , Lipoprotein lipase/biosynthèse , Cellules souches mésenchymateuses/effets des médicaments et des substances chimiques , Ostéoblastes/effets des médicaments et des substances chimiques , Ostéogenèse/effets des médicaments et des substances chimiques , Récepteur PPAR gamma/biosynthèse , Hormone parathyroïdienne/pharmacologie , Fragments peptidiques/pharmacologie , Récepteur de la parathormone de type 1/antagonistes et inhibiteurs
SÉLECTION CITATIONS
Détails de la recherche